This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Hyperion Therapeutics Announces Second Quarter 2012 Operating Results

Selling and marketing expenses for the quarter ended June 30, 2012 were $0.6 million, compared to $0.2 million for the quarter ended June 30, 2011. The increase was primarily due to increases in consulting fees and personnel costs as we prepare for the potential commercialization of Ravicti in UCD.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion Therapeutics is developing Ravicti™ (glycerol phenylbutyrate) for two orphan indications: urea cycle disorders and hepatic encephalopathy.

Forward-Looking Statements:

To the extent that statements contained in this press release are not descriptions of historical facts regarding Hyperion, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our expectations regarding the timing of any commercial launch of Ravicti as well as the use of the initial public offering proceeds. Forward-looking statements in this release involve substantial risks and uncertainties that could cause future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks related to: the uncertain clinical development process; that the U.S. Food and Drug Administration may not be satisfied with preclinical data, including carcinogenicity data; the ability to obtain, and timing of, regulatory approval of Ravicti for the treatment of UCD or the success and timing of commercialization efforts; the fact that the patient population suffering from UCD is small and has not been established with precision; the ability to obtain adequate clinical supplies of Ravicti; and the ability to raise sufficient capital to complete the development and commercialize Ravicti in UCD. Hyperion undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see the company's prospectus dated July 25, 2012, filed with the Securities and Exchange Commission.

 
 
Hyperion Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
(Unaudited)
 
  Three Months Ended June 30, Six Months Ended  June 30,
  2012 2011 2012 2011
     
Operating expenses        
Research and development $ 2,732  $ 4,632  $ 11,640  $ 8,932
General and administrative  1,469  2,488   3,540   3,849
Selling and marketing  554   217   800   467
         
Total operating expenses  4,755   7,337   15,980   13,248
         
Loss from operations  (4,755)  (7,337)  (15,980)  (13,248)
Interest income  3   10   7   14
Interest expense  (1,282)  (849)  (2,322)  (849)
Other income (expense), net  (1,128)  52   (753)   52
         
Net loss attributable to common stockholders $ (7,162) $ (8,124) $ (19,048) $ (14,031)
Net loss per share attributable to common stockholders:        
Basic and diluted $ (15.26) $ (17.31) $ (40.59) $ (29.90)
Weighted average number of shares used to compute net loss per share of common stock:        
Basic and diluted  469,319   469,319   469,319   469,319
         
 
Hyperion Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
 
  June 30, December 31,
  2012 2011
Assets    
Current assets    
Cash and cash equivalents $ 7,299 $ 7,018
Prepaid expenses and other current assets  436  741
Restricted cash  —  305
     
Total current assets  7,735  8,064
     
Deferred offering costs  1,375  —
Property and equipment, net  25  19
Restricted cash  —  25
Other non-current assets  447  34
     
Total assets $ 9,582 $ 8,142
     
Liabilities, Convertible Preferred Stock and Stockholders' Deficit    
Current liabilities    
Accounts payable $ 1,955 $ 1,887
Accrued liabilities  4,329  3,310
Call option liability  —  737
Convertible notes payable  31,153  23,412
Notes payable, current portion  1,705  —
     
Total current liabilities  39,142  29,346
Warrants liability  4,566  2,574
Notes payable, net of current portion  7,651  —
Total liabilities  51,359  31,920
     
Convertible preferred stock 58,326 58,326
     
Stockholders' deficit:    
Common stock  —  —
Additional paid-in capital  25,679  24,630
Deficit accumulated during the development stage  (125,782)  (106,734)
Total stockholders' deficit  (100,103)  (82,104)
Total liabilities, convertible preferred stock and stockholders' deficit $ 9,582 $ 8,142
     
CONTACT: Shari Annes, Investor Relations
         Cell: 650 888 0902
         sannes@annesassociates.com

2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,171.69 -108.05 -0.63%
S&P 500 1,991.54 -18.86 -0.94%
NASDAQ 4,514.5670 -65.2220 -1.42%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs